Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00256880 · ClinicalTrials.gov registry record · Phase 2
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
A Phase 2 study of Carcinoma, Renal Cell, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 8
- Study locations
NCT00256880: Completed Phase 2 study of Carcinoma, Renal Cell, sponsored by GlaxoSmithKline.
NCT00256880 is a Phase 2 study of Carcinoma, Renal Cell that has completed, run by GlaxoSmithKline. The registered enrollment target is 100 participants, below the 280-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (64% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00256880, a Phase 2 study of Carcinoma, Renal Cell, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing. A patient may continue to receive the treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.
Conditions Studied
Interventions
- DRUG GW786034
Study Locations (8)
Victoria
- GSK Investigational Site - East Melbourne
- GSK Investigational Site - Melbourne
- GSK Investigational Site - Melbourne
Arkansas
- GSK Investigational Site - Little Rock
Massachusetts
- GSK Investigational Site - Boston
North Carolina
- GSK Investigational Site - Durham
Pennsylvania
- GSK Investigational Site - Philadelphia
Washington
- GSK Investigational Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00256880 record still lists
NCT00256880 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 280-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which GW786034 is the first listed.
NCT00256880 lists 8 locations in 6 states (Victoria, Arkansas, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00256880 about?
NCT00256880 is a clinical study titled "Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma". The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing. A patient may continue to receive the treatment as long as they are benefiting from the treatment. Bl...
What is the current status of trial NCT00256880?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2005-01. Estimated completion is 2005-12.
What conditions does trial NCT00256880 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell.
What interventions are being tested in trial NCT00256880?
The interventions under investigation include: GW786034 (DRUG).
Who is sponsoring clinical trial NCT00256880?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00256880 being conducted?
This trial has 8 study locations across Arkansas, Massachusetts, North Carolina, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00256880's enrollment target sits among peer trials
100 17th of 34 higher than 18 of 34 other Carcinoma, Renal Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Renal Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Dendritic Cell Vaccine in Kidney Cancer
RECRUITING · Phase 2
-
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
COMPLETED · Phase 2
-
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
COMPLETED · Phase 2
-
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
COMPLETED · Phase 2
-
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia